Cellular Logistics today announced the publication of an article in Nature Communications that details a cell-production advancement with significant positive implications for the commercialization of the company’s Tandem™ technology.
MADISON, Wis., June 25, 2019 – Cellular Logistics today announced the publication of an article in Nature Communications that details a cell-production advancement with significant positive implications for the commercialization of the company’s Tandem™ technology. The article,
The article describes the results of work by Cellular Logistics’ co-founders Eric Schmuck, Ph.D., Amish Raval, M.D., Tim Camp, M.D., Ph.D., and others to develop a perpetual source of cells to produce the company’s Tandem™ technology. The creation of this perpetual cell source will enable the company to scale the production of its Tandem™ HF product.
Cardiac fibroblasts (CFs) play critical roles in heart development and disease. Human pluripotent stem cells (hPSCs) provide a highly renewable source for these cells, but an efficient method of producing CFs from hPSCs had not been described until publication.
The work of Drs. Schmuck, Raval, Camp and others described in the Nature Communications paper shows the differentiation of hPSCs and their generation of progenitor or precursor cells that efficiently give rise to hPSC-CFs.
The hPSC-CFs resemble native heart CFs in form and structure, growth, and production of the extracellular matrix that is the foundation of CL’s Tandem™ technology, and other important biological functions. The hPSC-CFs generated by this method provide a powerful cell source for research, drug discovery, precision medicine, and therapeutic applications in cardiac regeneration.
About Cellular Logistics
Cellular Logistics is focused on improving patient outcomes and the quality of life of heart disease patients. Our pioneering Tandem™ platform technology promises to radically change patient treatment in the aftermath of a heart attack by delivering therapies to the right location in the heart and providing a novel cellular scaffolding that ensures therapy retention and promotes healing.
Founded by visionary, trusted clinicians and scientists, we are not only developing new ways to deliver heart treatments, we are creating an entirely new market for companion therapy products. Our dedication to improving the lives of patients coupled with our commitment to remaining innovative and collaborative enables us to deliver a truly differentiated therapeutic product for the treatment of cardiac disease.
Contact
Alex Vodenlich
President & CEO
(608) 217-5587
alex@cellogistics.com
